# Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years

> **NCT05429918** · — · UNKNOWN · sponsor: **Peking University Third Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05429918
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-30
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-06-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05429918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05429918, "Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05429918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*